Emily M. Leproust - 06 Nov 2024 Form 4/A - Amendment Insider Report for Twist Bioscience Corp (TWST)

Role
Chief Executive Officer, Director
Signature
/s/ Dennis Cho, as Attorney-in-Fact for Emily M. Leproust
Issuer symbol
TWST
Transactions as of
06 Nov 2024
Net transactions value
-$639,368
Form type
4/A - Amendment
Filing time
15 Nov 2024, 16:05:13 UTC
Date Of Original Report
08 Nov 2024
Previous filing
06 Nov 2024
Next filing
13 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TWST Common Stock Sale $639,368 -14,334 -2.4% $44.60 589,552 06 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TWST Employee Stock Option (right to buy) 0 06 Nov 2024 Common Stock 0 $5.95 Direct F2
holding TWST Employee Stock Option (right to buy) 150,879 06 Nov 2024 Common Stock 0 $8.82 Direct F3
holding TWST Employee Stock Option (right to buy) 266,539 06 Nov 2024 Common Stock 0 $26.66 Direct F4
holding TWST Employee Stock Option (right to buy) 131,290 06 Nov 2024 Common Stock 0 $23.33 Direct F5
holding TWST Employee Stock Option (right to buy) 64,950 06 Nov 2024 Common Stock 64,950 $67.85 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance Stock Units ("PSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2 The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F3 The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F4 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F5 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F6 Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

Remarks:

The transactions and holdings reported on this amended filing were previously reported on the Form 4 filed by the reporting person on November 8, 2024 and have been included in this amendment for reference only. This amended filing is being made solely to amend footnote 1.